Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yang Xin Granules (养心颗粒) is a Traditional Chinese Medicine (TCM) formulation developed for the treatment of cardiovascular conditions, specifically chronic stable angina. As a hospital-specific preparation (院内制剂) developed by the First Affiliated Hospital of Heilongjiang University of Chinese Medicine, it is designed to nourish the heart (Yang Xin) and promote blood circulation to resolve stasis. The formulation typically consists of multiple botanical extracts aimed at reducing the frequency of angina attacks, improving myocardial ischemia, and enhancing exercise tolerance. In clinical settings, it is often evaluated as an adjunctive therapy to standardized Western medical treatments, such as antiplatelet agents and nitrates, for patients with coronary heart disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yang Xin Granules.